Skip Navigation


Carcinogenesis Advance Access originally published online on June 9, 2008
Carcinogenesis 2008 29(7):1407-1414; doi:10.1093/carcin/bgn118
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/7/1407    most recent
bgn118v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schwab, M.
Right arrow Articles by Stein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwab, M.
Right arrow Articles by Stein, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells

Markus Schwab*, Veerle Reynders, Stefan Loitsch, Yogesh M. Shastri, Dieter Steinhilber1, Oliver Schröder and Jürgen Stein

First Department of Medicine–ZAFES, Johann Wolfgang Goethe-University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
1 Institute of Pharmaceutical Chemistry–ZAFES, Johann Wolfgang Goethe-University Frankfurt, Max-von-Laue-Strasse 9, 60438 Frankfurt am Main, Germany

* To whom correspondence should be addressed. Division of Gastroenterology, First Department of Medicine–ZAFES, Johann Wolfgang Goethe-University Frankfurt, 60590 Frankfurt am Main, Germany. Tel: +49 69 6301 5324; Fax: +49 69 6301 6246; Email: m.schwab{at}med.uni-frankfurt.de

Purpose: Mesalazine has been identified as a candidate chemopreventive agent in colon cancer prophylaxis because of its pro-apoptotic and anti-proliferative effects. However, the precise mechanisms of action are not entirely understood. The aim of our study was to investigate the involvement of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) in mesalazine's anticarcinogenic actions in colorectal cancer cells. Experimental design: The effects of mesalazine on cell cycle distribution, cell count, proliferation and caspase-mediated apoptosis were examined in Caco-2, HT-29 and HCT-116 cells used as wild-type, dominant-negative PPAR{gamma} mutant and empty vector cultures. We focused on caspase-3 activity, cleavage of poly(ADP-ribose) polymerase (PARP), caspase-8 and caspase-9, as well as on expression of survivin, X-linked inhibitor of apoptosis (Xiap), phosphatase and tensin homolog deleted from chromosome ten (PTEN) and c-Myc. Techniques employed included transfection assays, immunoblotting, flow cytometry analysis, colorimetric and fluorometric assays. Results: Mesalazine caused a time- and dose-dependent decrease in both cell growth and proliferation. Growth inhibition was accompanied by a G1/G0 arrest, a significant increase in PTEN, caspase-3 activity, cleavage of PARP and caspase-8, whereas the expressions of Xiap, survivin and c-Myc were decreased simultaneously. Cleavage of caspase-9 was not observed. Moreover, PPAR{gamma} expression and activity were elevated. The growth-inhibitory effect of mesalazine was partially reduced in dominant-negative PPAR{gamma} mutant cells, whereas the expression of c-Myc was not affected. Mesalazine-mediated increased caspase-3 activity, the expression of PTEN, cleavage of PARP and caspase-8 as well as reduced levels of survivin and Xiap were completely abolished in the PPAR{gamma} mutant cell lines. Conclusion: This study clearly demonstrates that mesalazine-mediated pro-apoptotic and anti-proliferative actions are regulated via PPAR{gamma}-dependent and -independent pathways in colonocytes.

Abbreviations: 5-ASA, 5-aminosalicylate; CRC, colorectal cancer; G418, Geneticin 418 sulphate; IAP, inhibitor of apoptosis protein; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; PARP, poly(ADP-ribose) polymerase; PBS, phosphate-buffered saline; PPAR{gamma}, peroxisome proliferator-activated receptor {gamma}; PTEN, phosphatase and tension homolog deleted from chromosome ten; UC, ulcerative colitis; Xiap, X-linked inhibitor of apoptosis

Received January 3, 2008; revised May 6, 2008; accepted May 6, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Van Themsche, V. Leblanc, S. Parent, and E. Asselin
X-linked Inhibitor of Apoptosis Protein (XIAP) Regulates PTEN Ubiquitination, Content, and Compartmentalization
J. Biol. Chem., July 31, 2009; 284(31): 20462 - 20466.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. J. Koelink, E. C. Robanus-Maandag, P. Devilee, D. W. Hommes, C. B.H.W. Lamers, and H. W. Verspaget
5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model
Carcinogenesis, July 1, 2009; 30(7): 1217 - 1224.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.